La cadena de opciones muestra datos clave de las opciones de acciones de CERo Therapeutics Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CERo Therapeutics Hldgs..

CERo Therapeutics Hldgs (NASDAQ:CERO) Bolsa, Cadena de Opciones

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

JPMorgan analyst Cory Carpenter downgraded Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) stock from <a href="https://www.benzinga.com/quote/GETY/analyst-ratings" target="_blank" rel="noreferrer noopener">Neutral to Underweight</a>. The stock price declined after the rerating.
Getty Images is a leading visual content creator and marketplace that connects over 576,000 content creators with 719,000 purchasing customers.
Also Read: <a target="_blank" href="https://www.benzinga.com/tech/24/12/42536593/verizon-teams-up-with-nvidia-to-power-ai-apps-over-private-5g-networks" rel="noreferrer noopener">Verizon Teams Up With Nvidia To Power AI Apps Over Private 5G Networks</a>
The rerating reflects Getty Images stock trading at a healthy premium to Shutterstock Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSTK#NYSE">SSTK</a>), uncertainty around the potential longer-term impact from generative AI on the industry, potential growth headwinds in 2025 (lapping even-year events + FX) and limited capital allocation flexibility.
Getty Images returned to growth in recent quarters driven by a strong event calendar (U.S. election and Olympics), lapping easier Hollywood strike comps and agency channel stability.
Carpenter expects these trends to persist in the fourth quarter but noted the 2025 setup will be more challenging as the event calendar turns into a ~$10 million-$12 million headwind and Getty Images has high foreign exchange exposure relative to the rest of the analyst&#8217;s coverage universe.
Carpenter expects this to translate into limited revenue growth and margin expansion in 2025. This, coupled with ongoing uncertainty around the potential longer-term impact of generative AI on the industry, Getty Images trading at a healthy premium to Shutterstock, warrant litigation overhang and limited capital allocation flexibility, gives the analyst a cautious bias on the stock next year.
GETY Price Action: Getty Images stock is down 4.67% at $2.45 at publication Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42536024/taiwan-eyes-amazons-kuiper-as-starlink-faces-hurdles" target="_blank" rel="noreferrer noopener">Amazon&#8217;s Project Kuiper In Talks With Taiwan For Satellite Partnership</a></li>
</ul>
Photo: Shutterstock

Downgrades

Price Target

Analyst Ratings

Movers

Media

GETY

SSTK

Getty Images' AI Uncertainty, FX Headwinds, Premium Valuation Spark Downgrade

WIIM

MULN

Mullen Automotive shares are trading higher after the company announced 100 Class 1 and Class 3 EV shipments for sales totaling $5.5 million. Additionally, the company reduced its monthly burn rate since August 2024

XCHG Shares Resume Trade Then Again Halted On Circuit Breaker To The Downside, Stock Now Down -92.2%

Nukkleus shares are trading higher on continued momentum after the company recently announced it has acquired a 51% controlling stake in Star 26 Capital.

Macquarie analyst Steve Koenig maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Neutral and maintains $370 price target.

Macquarie Maintains Neutral on Salesforce, Maintains $370 Price Target

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 387.2%

SMTK

SmartKem shares are trading higher after the company announced it received a £900,000 grant from Innovate UK and commenced a $7.65 million offering of common stock and Class D warrants.

JPMorgan analyst Doug Anmuth has rolled out an optimistic<a href="https://www.benzinga.com/markets/24/12/42497093/stock-market-predictions-for-2025-a-mixed-bag-of-expectations"> internet 2025 outlook</a>, emphasizing mega-cap tech leaders as top picks. The big winners? Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google, and Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>). 
Despite "heavy capex investments," Anmuth expects "increasing returns" as artificial intelligence shifts to practical applications, driving growth in advertising, cloud, and software tools.
<h2 class="wp-block-heading">Why 2025 Looks Promising</h2>
Anmuth highlights three transformative AI trends reshaping the tech landscape:
<ol>
<li>A 30% boost in engineering efficiency across major companies.</li>
<li>Billions in AI revenue for AWS and Google Cloud.</li>
<li>Accelerated ad and search growth for Meta and Google, driven by improved targeting and conversions.</li>
</ol>
These advancements, coupled with a pro-business political backdrop and stabilized macro trends, are set to support strong revenue growth across the Internet sector in 2025.
Read Also: <a href="https://www.benzinga.com/24/12/42556006/amazon-to-rally-around-21-here-are-10-top-analyst-forecasts-for-wednesday">Amazon To Rally Around 21%?</a>
<h2 class="wp-block-heading">Capex Surge: A Long-Term Play</h2>
Big tech is gearing up for significant infrastructure spending in 2025, exceeding market expectations. 
Anmuth projects capex of $97 billion for Amazon, $64 billion for Meta, and $62 billion for Alphabet. While these investments may weigh on margins, the long-term outlook remains bullish. 
Amazon and Alphabet are forecasted to expand margins and free cash flow, while Meta's outlook is steadier, despite double-digit revenue and EPS growth expectations.
<h2 class="wp-block-heading">Stock-Specific Highlights</h2>
<ul>
<li>Amazon (Target Price: $280) Amazon&#8217;s dominance in e-commerce and cloud markets positions it for multi-year margin and free cash flow expansion. With high-growth AWS and advertising streams, the company is poised to capitalize on untapped potential in IT and retail digitization.</li>
<li>Alphabet (Target Price: $232) Alphabet's ad business and AI-driven innovation keep it ahead of the pack. Search, YouTube ads, and cloud services present robust growth opportunities, while its "Other Bets" businesses like Waymo and Verily add optionality.</li>
<li>Meta Platforms (Target Price: $725) Meta's dual focus on AI and the metaverse underscores its commitment to long-term growth. Despite increased infrastructure spending, Meta's unmatched reach and targeting capabilities ensure sustained profitability and value for advertisers.</li>
<li>Spotify (Target Price: $555) Spotify continues to ride the audio streaming wave with solid user growth, cost discipline, and profit gains from podcasts and marketplace contributions.</li>
</ul>
As AI matures, these mega-cap tech leaders are well-positioned to reap the rewards of their massive investments. 
While elevated capex may challenge short-term margins, the broader narrative of innovation, efficiency, and market dominance paints a bullish picture for 2025. 
For investors, JPMorgan's favorites—Amazon, Meta, Alphabet, and Spotify—stand as compelling opportunities to capitalize on the next phase of tech evolution.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42548075/us-stock-markets-outsized-influence-resurges-as-it-dominates-two-thirds-of-msci-world-indexs-capitalization-mirroring-late-1980s-peak">US Stocks Led By Apple, Nvidia, And Other Tech Giants Dominate Nearly Two-Thirds Of MSCI World Index, Drawing Parallels To 1980s Peak</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Long Ideas

Tech

AMZN

GOOG

GOOGL

SPOT

Amazon, Meta, Alphabet, Spotify Lead JPMorgan's 2025 Tech Picks For AI Potential

Meta Platforms Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) Instagram has the potential to generate 50% of the company&#8217;s advertising revenue in the U.S., Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2024-12-18/instagram-expected-to-generate-50-of-meta-s-us-ad-sales-in-2025?sref=TBDibEcD" rel="noreferrer noopener">cites</a> from Emarketer estimates.
Instagram could breach $32 billion in U.S. advertising revenue in 2025, up over 24% in 2024, as its short-form video product Reels gain traction, Bloomberg cites Emarketer. The video-sharing app boasts over 148 million American users.
Also Read: <a target="_blank" href="https://www.benzinga.com/media/24/12/42554393/disneys-marvel-rivals-game-hits-20-million-players-proves-superhero-power-still-reigns" rel="noreferrer noopener">Disney&#8217;s Marvel Rivals Game Hits 20 Million Players, Proves Superhero Power Still Reigns</a>
By early 2022, Instagram accounted for nearly 30%&nbsp;of Meta&#8217;s global business from 27% in 2021, Bloomberg cited court filings.
Reels competes with ByteDance&#8217;s TikTok and Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) YouTube Shorts.
Meta&#8217;s focus on video content has been instrumental to its growth, as users devoted nearly 67% of their Instagram time to surfing videos, Bloomberg cited Jasmine Enberg of Emarketer.
<a target="_blank" href="https://www.benzinga.com/24/12/42369266/meta-reddit-stocks-climb-record-highs-as-tiktoks-battle-against-us-ban-continues-after-court-ruling" rel="noreferrer noopener">The TikTok ban</a> could serve as a tailwind for Instagram, helping it win over 20% of reallocated TikTok ad dollars in the U.S, Reuters cites Enberg.
Meta previously told Instagram Reels accounted for over 50%&nbsp;of the time people spend on the app.
In 2024, 53.7% of Instagram&#8217;s ad revenue primarily came from its Feed features and 24.6% from Stories features. With Reels&#8217; revenue boost, the combined revenue share from Instagram Explore, Reels, and Threads could rise 9.6% in 2025.
In October, BofA Securities analyst Justin Post <a target="_blank" href="https://www.benzinga.com/news/24/10/41465662/metas-reels-monetization-and-ai-innovations-drive-top-ai-pick-analyst" rel="noreferrer noopener">projected Meta&#8217;s upside</a> from ramping up Messaging and Reel monetization powered by new artificial intelligence tools and CRM integration.
Meta Platforms stock surged 79% year-to-date. Investors can gain exposure to the stock through Vanguard Communication Services ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOX#NYSE">VOX</a>) and The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>).
<h2 class="wp-block-heading">Is Meta A Good Stock To Buy?</h2>
An investor or trader's decision to buy or sell a stock is unique to their time horizon and risk tolerance. Many typical investors evaluate earnings growth and valuation on a particular stock before making a decision. 
For example, for Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), you'll notice that earnings in its last quarter grew 14.86% <a href="https://www.benzinga.com/quote/META/earnings">source</a>. As an investor, you'll want to decide whether that's better or worse than what you'd like to see among stocks in your portfolio. 
On the valuation side, Meta Platforms's price to earnings ratio &#8211; a measure of how much an investor pays for the company's earnings &#8211; is compressed 15.56% in the current quarter when compared with last year. That places it below similar businesses Alphabet, Baidu, Pinterest in its sector. You'll need to decide whether that makes it more or less attractive based on how you think the company will perform over time.
There are many different valuation metrics that may help you make a decision. Find more on <a href="https://www.benzinga.com/quote/META">Meta Platforms's quote page</a>, or if you'd like a deeper dive in an advanced program, try <a href="https://pro.benzinga.com">Benzinga PRO</a> for free.
Price Action: META stock is up 1.15% at $626.545 at the last check on Wednesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42553094/jabil-q1-earnings-tops-expectations-cloud-and-data-center-growth-outlook" target="_blank" rel="noreferrer noopener">Jabil Q1 Earnings: Revenue And EPS Beat, Cloud and Data Center Growth, Raises Annual Outlook</a></li>
</ul>
Photo via Shutterstock

Instagram's Ad Revenue Could Hit $32 Billion by 2025, Driving Meta's Growth: Report

AZTA

Azenta shares are trading higher after Stephens & Co. upgraded the stock to Overweight from Equal-Weight and raised its price target from $50 to $60.

Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) stock is trading higher on Wednesday after the company announced it secured a 400 MWh <a href="https://www.benzinga.com//node/42552632">standalone storage order</a> with International Electric Power.
The Details: This order is part of a project to be deployed at Marine Corps Base Camp Pendleton in San Diego, California which aims to enhance grid resiliency for the U.S. Navy and Marine Corps.
The project, supported by funding from the California Energy Commission's Long Duration Energy Storage Program, will use Eos Z3 batteries and is scheduled for delivery beginning in 2025. The Eos Z3 Cubes are safe, non-flammable and don't require cooling systems, which helps minimize noise and reduce operational costs.
&#8220;IEP and CEC are at the forefront of North American long-duration energy storage, and their partnership has been invaluable as Eos transitions into a profitable operating company. They recognize the need for multiple storage technologies and the energy security that an American-made product provides,&#8221; added Joe Mastrangelo, Eos CEO.
&#8220;It&#8217;s an honor to have been selected for such an important installation at Camp Pendleton.&#8221;
Related Link: <a href="https://www.benzinga.com/insights/options/24/12/42557838/palantir-technologies-unusual-options-activity">Palantir Technologies Unusual Options Activity</a>
EOSE Price Action: At the time of writing Eos Energy stock is trading 14.7% higher at $4.48, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Shutterstock

EOSE

What's Going On With Eos Energy Stock Wednesday?

Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TH#TSX">TH</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THTX#NASDAQ">THTX</a>), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) describing the changes made to the manufacturing environment of the facility where EGRIFTA SV&#xAE; is produced. A PAS is reviewed by the FDA within four months of receipt and an approval is needed prior to the distribution of the <a href="https://www.globenewswire.com/Tracker?data=8zHQ9qiyFO30h9BOfieWluYkNSdMsyvq24uHfuCufIVJuAcz2MC2Wi8JwO3uxPJK5Zg4Hnxe9yRK0YL8b-VwzIBT6sI1dIqefPxyrQH9SQcGs96Be7BtzwxdO12cw4ciN0DBUaDXb2Ey9HpTsYJ1aBwYpdHX5l1dgbBweAE30nUjyjJdJMuySCqOg_9-Q9R4FdrlVrl3X8KTmjgYmunrjBVx1NwAWJWd66efKQ6DFRo=">recently manufactured</a> batches of&nbsp;EGRIFTA SV&#xAE;.
Existing inventory levels of&nbsp;EGRIFTA SV&#xAE; are expected to meet patient demand until mid-January 2025. Theratechnologies therefore continues discussions with the relevant FDA divisions in an effort to accelerate the release of EGRIFTA SV&#xAE; and avoid a product shortage at the patient level.
The Company will update the market on any further material developments.
EGRIFTA SV&#xAE; is distributed in the United States only.

Biotech

General

THTX

TSX:TH

Theratechnologies Has Submitted A Prior Approval Supplement To The U.S. FDA Describing The Changes Made To The Manufacturing Environment Of The Facility Where EGRIFTA SV Is Produced

QBTS

D-Wave Quantum shares are trading higher amid continued volatility in quantum stocks.

<a href="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr" title="https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr">https://economictimes.indiatimes.com/tech/funding/bureau-secures-30-million-from-sorenson-capital-paypal-ventures-existing-investors/articleshow/116406362.cms?from=mdr</a>

Contracts

PYPL

Reported Earlier, 'Bureau Secures $30M From Sorenson Capital, PayPal Ventures, Existing Investors' - Economic Times

In the current session, the stock is trading at $93.06, after a 0.44% spike. Over the past month, Lantheus Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNTH#NASDAQ">LNTH</a>) stock increased by 7.65%, and in the past year, by 56.81%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_0.png" alt="Past Year Chart" />

<h3>Lantheus Holdings P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Lantheus Holdings has a lower P/E than the aggregate P/E of 48.6 of the Health Care Equipment &amp; Supplies industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1734546613_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

LNTH

P/E Ratio Insights for Lantheus Holdings

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 377%

Nukkleus Inc Shares Resume Trading

EGHT

8x8 shares are trading higher after Morgan Stanley raised its price target on the stock from $2 to $2.6.

Micron Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) heads into its <a href="https://www.benzinga.com/quote/MU/earnings">first-quarter earnings</a> announcement with a mix of optimism and caution.
<h1 class="wp-block-heading">"Choppy Quarters Ahead"?</h1>
As Jake Silverman, Bloomberg Intelligence Semiconductor Analyst, puts it, "choppy quarters ahead for NAND" could pose a challenge, with pricing and inventory pressures in the smartphone and PC markets.
However, the analyst also highlights AI-related applications as a potential offset, giving Micron a chance to weather the storm.
Read Also: <a href="https://www.benzinga.com/24/12/42553082/how-to-earn-500-a-month-from-micron-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Micron Stock Ahead Of Q1 Earnings</a>
<h1 class="wp-block-heading">Bullish Technical Signals Keep Optimists In The Game</h1>
Micron's stock, currently trading at $110.93, flashes bullish signs across key technical indicators. 
<figure class="wp-block-image size-full"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="630" height="493" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png" alt="" class="wp-image-698134" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM.png 630w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18114211/Screenshot-2024-12-18-at-10.11.43-PM-300x235.png 300w" sizes="(max-width: 630px) 100vw, 630px" /></a></figure>
<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent121824&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
It sits well above short- and medium-term moving averages, with the eight-day simple moving average (SMA) at $103.94, the 20-day SMA at $102.07 and the 50-day SMA at $104.07. 
The Moving Average Convergence Divergence (MACD) at 1.15 also suggests momentum is on the bulls' side.
However, the 200-day SMA of $110.93 coincides with the price, remaining a hurdle, signaling a potential resistance level.
<h1 class="wp-block-heading">AI: A Light At The End Of The NAND Tunnel?</h1>
The market will be laser-focused on how Micron balances the dynamics of two divergent forces:
<ol>
<li>NAND Weakness: Elevated inventories and pricing pressure.</li>
<li>AI Opportunities: As Silverman notes, secular growth in AI applications could provide a much-needed boost, potentially offsetting the broader NAND market challenges.</li>
</ol>
<h1 class="wp-block-heading">What's Expected?</h1>
Analysts estimate an EPS of $1.76 and revenue of $8.72 billion. But beyond these numbers, investors will be scrutinizing the company's guidance. Can Micron sustain its AI-driven growth momentum, or will "choppy quarters" in NAND drag it down?
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/previews/24/12/42549182/us-stocks-to-open-higher-as-rate-cut-expectations-surge-all-eyes-on-dow-jones-to-break-its-9-day-losing-streak">US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak</a></li>
</ul>
Photo: NPS_87 on Shutterstock

Technicals

Previews

Micron Earnings: Will AI Growth Outweigh 'Choppy' Memory Market?

Nukkleus Shares Halted On Circuit Breaker To The Upside, Stock Now Up 319.6%

CERo Therapeutics files to sell 713.6M shares of common stock for holders

CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound CER-1236.

CERo Therapeutics' (CERO) Stock Sees Significant Climb After Revealing Ovarian Cancer Data

FOXO Technologies, CERo Therapeutics Holdings, and Mullen Automotive are the 3&nbsp;Penny Stocks&nbsp;to watch on November 14, 2024, based on&nbsp;...

3 Penny Stocks to Watch Now, 11/24/24

CERo Therapeutics (CERO) announces that the U.S. Food and Drug Administration has cleared the Company's Investigational New Drug Application for Ph...

Cero Therapeutics receives FDA clearance of IND application for CER-1236

CERo Therapeutics Holdings, Simpple Ltd., and Arena Group Holdings are the 3&nbsp;Penny Stocks&nbsp;to watch on November 19, 2024, based on&nbsp;Ti...

3 Penny Stocks to Watch Now, 11/19/24

06:23 EST Cero Therapeutics (CERO) files to sell 210M shares of common stock for holders Published first on TheFly – the ultimate source for real-t...

Cero Therapeutics files to sell 210M shares of common stock for holders

CERo Therapeutics (CERO) announces its Board of Directors has appointed Chris Ehrlich as CEO. Previously he held the position of Interim CEO. Publi...

Cero Therapeutics names Chris Ehrlich as CEO

Cero Therapeutics (CERO) announced its board of directors has appointed Chris Ehrlich as CEO. Previously he held the position of interim CEO. In ad...

Cero Therapeutics appoints Chris Ehrlich as CEO

CERo Therapeutics Holdings ( ($CERO) ) just unveiled an announcement. CERo Therapeutics, an innovative immunotherapy company, has appointed Chris E...

CERo Therapeutics Appoints New CEO to Lead Innovations

CERo Therapeutics appoints Chris Ehrlich CEO

AREN

FOXO

LPAA

SPPL

Press Releases

CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236

Manitoba Woman Beats Stage 4 Cancer with Breakthrough CAR T-Cell Therapy

Health Care

CERo Therapeutics, Inc. Completes IND-Enabling Activities Following Successful Manufacturing Runs for Lead Compound CER-1236

CERo Therapeutics, Inc. Presents CER-1236 Data Supporting Use in AML at Global Cell & Gene Therapy Summit 2024

CERo Therapeutics, Inc. Announces Financing and Provides Update on Investigational New Drug Application for CER-1236

CERo Therapeutics, Inc. Names Al Kucharchuk Chief Financial Officer and Kristen Pierce Chief Development Officer

CERo Therapeutics, Inc. Provides Corporate Update

CERo Therapeutics, Inc. Presents Preclinical Data Demonstrating CER-1236 Killing Ovarian Cancer Cell Lines Without Toxicity

CERo Therapeutics, Inc. Receives FDA Clearance of Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Its Lead Compound CER-1236 in Acute Myelogenous Leukemia

Comments

CERo Therapeutics Hldgs

CERo Therapeutics Hldgs (CERO) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL